10X Genomics (TXG) PT Lowered to $14 at Goldman Sachs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts TXG Hot Sheet
Price: $71.55 +2.58%
Rating Summary:
7 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Rating Summary:
7 Buy, 13 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 14 | New: 15
Join SI Premium – FREE
Goldman Sachs analyst Matthew Sykes lowered the price target on 10X Genomics (NASDAQ: TXG) to $14.00 (from $16.00) while maintaining a Sell rating.
You May Also Be Interested In
- Stephens Downgrades 10X Genomics (TXG) to Equal Weight
- Zymeworks (ZYME) PT Raised to $52 at Jefferies
- Lockheed Martin (LMT) PT Raised to $692 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
